The estimated Net Worth of Thomas A Boyd is at least $281 Tysiąc dollars as of 1 July 2010. Thomas Boyd owns over 2,675 units of Progenics Pharmaceuticals stock worth over $162,110 and over the last 20 years Thomas sold PGNX stock worth over $119,325.
Sign up
Thomas Boyd PGNX stock SEC Form 4 insiders trading
Thomas has made over 35 trades of the Progenics Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Thomas exercised 2,675 units of PGNX stock worth $11,877 on 1 July 2010.
The largest trade Thomas's ever made was exercising 10,000 units of Progenics Pharmaceuticals stock on 15 February 2006 worth over $136,300. On average, Thomas trades about 2,059 units every 55 days since 2004. As of 1 July 2010 Thomas still owns at least 39,539 units of Progenics Pharmaceuticals stock.
You can see the complete history of Thomas Boyd stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Progenics Pharmaceuticals
Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over $11,559,939 worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth $11,900,148 . The most active insiders traders include Healthcare Master Fund Ltd ..., Michael D Kishbauch oraz Bradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of $60,241. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth $359,395.
What does Progenics Pharmaceuticals do?
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
What does Progenics Pharmaceuticals's logo look like?
Complete history of Thomas Boyd stock trades at Progenics Pharmaceuticals
Progenics Pharmaceuticals executives and stock owners
Progenics Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Partners, Llc Melkonian Cap...,
-
Nicole Williams,
Director -
Healthcare Master Fund Ltd ...,
-
Healthcare Master Fund Ltd ...,
-
Sheldon Hirt,
Executive VP & General Counsel -
Michael D Kishbauch,
Director -
David A Scheinberg,
Director -
Karen Jean Ferrante,
Director -
Peter J Crowley,
Director -
Bradley L Campbell,
Director -
Jeffery Summer,
SVP, Digital Technology -
Patrick Fabbio,
CFO -
Mark Robert Baker,
CEO -
Charles A Baker,
Director -
Kurt W Briner,
Director -
Stephen P Goff,
Director -
Mark F Dalton,
Director -
Thomas A Boyd,
SR. VP, Product Development -
Paul F Jacobson,
Director -
Robert A Mckinney,
VP of Finance and Admin -
Alton B Kremer,
VP, Clinical Research -
Robert J Israel,
Senior VP Medical Affairs -
Philip K Yachmetz,
VP, Gen Counsel and Secretary -
Ronald J Prentki,
President -
William C Olson,
Senior VP, Research and Develo -
Paul J Maddon,
Director -
Angelo William Jr Lovallo,
Vice President Finance -
Hagop Youssoufian,
Executive Vice President R&D -
Capital, L.P.Altiva Managem...,
-
Heinz Christoph Maeusli,
Director -
Gerard Ber,
Director -
Ann L. Mac Dougall,
Director -
Eric J Ende,
Director -
Vivien Wong,
EVP, Development -
David W. Mims,
Interim CEO and Interim CFO -
Bryce Tenbarge,
SVP, Commercial -
Benedict Osorio,
COO -
Asha Das,
Chief Medical Officer